12.1.31 Transmembrane Receptor Protein Tyrosine Kinase Activity
12.1.32 Unclassified
13 The Antibody-Target Interactome
14 The Progression and Maturity of Antibody Targets in Oncology: The
Preclinical Explosion
14.1 Target Profiles of Cancer Antibodies in Pre-Registration or on the
Market
14.2 New Cancer Antibody Targets in Phase III Clinical Development
14.3 New Cancer Antibody Targets in Phase II Clinical Development
14.4 New Cancer Antibody Targets in Phase I Clinical Development
14.5 New Cancer Antibody Targets in Preclinical Development
14.6 Development Profiles of All Identified Cancer Antibody Targets
15 Competitive Peer Group Profiling of Antibody Drugs by Cancer Indication
15.1 Biliary Cancer
15.2 Bladder Cancer
15.3 Bone Cancer
15.4 Brain Cancer
15.5 Breast Cancer
15.6 Cervical Cancer
15.7 Colorectal Cancer
15.8 Endometrial Cancer
15.9 Fallopian Tube Cancer
15.10 Gastrointestinal Cancer
15.10.1 Gastrointestinal Stomach Cancer
15.11 Head and Neck Cancer
15.12 Leukemia
15.12.1 Acute Lymphocytic Leukemia
15.12.2 Acute Myelogenous Leukemia
15.12.3 Chronic Lymphocytic Leukemia
15.12.4 Chronic Myelogenous Leukemia
15.13 Liver Cancer
15.14 Lung Cancer
15.14.1 Non-Small Cell Lung Cancer
15.14.2 Small Cell Lung Cancer
15.15 Lymphoma
15.15.1 B-Cell Lymphoma
15.15.2 Hodgkin' s Lymphoma
15.15.3 Non-Hodgkin' s Lymphoma
15.15.4 T-Cell Lymphoma
15.16 Melanoma
15.17 Mesothelioma
15.18 Myelodysplastic Syndrome
15.19 Myeloma
15.20 Nasopharyngeal Cancer
15.21 Neuroblastoma Cancer
15.22 Oesophageal Cancer
15.23 Ovarian Cancer
15.24 Pancreatic Cancer
15.25 Peritoneal Cancer
15.26 Prostate Cancer
15.27 Renal Cancer
15.28 Sarcoma
15.29 Supportive Care Indications
15.29.1 Chemotherapy-Induced Bone Marrow Injury
15.29.2 Chemotherapy-Induced Anemia
15.30 Thyroid Cancer
16 Cancer Antibodies and Their Targets by Companies
16.1 Australia
16.2 Belgium
16.3 Brazil
16.4 Canada
16.5 China
16.6 Cuba
16.7 Denmark
16.8 France
16.9 Germany
16.10 Israel
16.11 Italy
16.12 Japan
16.13 Netherlands
16.14 New Zealand
16.15 Norway
16.16 South Korea
16.17 Sweden
16.18 Switzerland
16.19 United Kingdom
16.20 USA
16.21 Non Industrial Bodies
17 Disclaimer
18 Drug Index
19 Company Index
4.1 List of Figures
Figure 1: Primary Sub-cellular Localization of Drug Targets
Figure 2: Visualization of Protein-Protein Interactions Among Antibody
Drug Targets
Figure 3: The Drug-Protein Interactome of Antibody Drugs in Oncology
Figure 4: Direct Head-to-Head Targeting Interactome of Cancer Antibody
Drugs
Figure 5: Competitive Peer Group Profiling Example
4.2 List of Tables
Table 1: Primary and Alternate Localization of Antibody Drug Targets
Table 2: Drug Targets of Cancer Antibodies Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
Table 3: Available Protein Expression Profiles of Antibody Drug Targets
Table 4: Pathway Summary
Table 5: Drug Targets Without any Identified Assigned Pathways
Table 6: Pathway Profile According to BioCarta of Cancer Antibody Drug
Targets
Table 7: Pathway Profile According to KEGG of Cancer Antibody Drug Targets
Table 8: Cancer Antibodies Targeting Major Singaling Pathways
Table 9: Protein-Protein Interactions Among Antibody Drug Targets
Table 10: Number of Available Biological Structures of Cancer Antibody
Targets
Table 11: Overview of Drug Target Profile Themes
Table 12: Antibody-Protein Interactome Clusters
Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes,
Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by
Developmental Stage
Table 14: Top 5 Pursued Cancer Antibody Targets
Table 15: Target Profiles of Cancer Antibodies in Pre-Registration or on
the Market
Table 16: New Cancer Antibody Targets in Phase III Clinical Development
Table 17: New Cancer Antibody Targets in Phase II Clinical Development
Table 18 New Cancer Antibody Targets in Phase I Clinical Development
Table 19: New Cancer Antibody Targets in Preclinical Development
Table 20: The Progression, Maturity and Competitive Comparison of Antibody
Drug Targets in Development
Table 21: Number of Cancer Antibody Drug Target Mixes Reported by Cancer
Indication
Table 22: Step 1 - Indication Profile of Peer Drugs
Table 23: Step 2 - All Peer Drugs with Known Cancer Indications
Table 24: Step 3 - Submarine Peer Drugs
Table 25: Step 4 -Target Overlap Drugs to Peer Drugs
Table 26: Drug Targets of Antibodies for the Treatment of Biliary Cancer
According to Developmental Stage of Antibody
Table 27: Drug Targets of Antibodies for the Treatment of Bladder Cancer
According to Developmental Stage of Antibody
Table 28: Drug Targets of Antibodies for the Treatment of Bone Cancer
According to Developmental Stage of Antibody
Table 29: Drug Targets of Antibodies for the Treatment of Brain Cancer
According to Developmental Stage of Antibody
Table 30: Drug Targets of Antibodies for the Treatment of Breast Cancer
According to Developmental Stage of Antibody
Table 31: Drug Targets of Antibodies for the Treatment of Cervical Cancer
According to Developmental Stage of Antibody
Table 32: Drug Targets of Antibodies for the Treatment of Colorectal
Cancer According to Developmental Stage of Antibody
Table 33: Drug Targets of Antibodies for the Treatment of Endometrial
Cancer According to Developmental Stage of Antibody
Table 34: Drug Targets of Antibodies for the Treatment of Fallopian Tube
Cancer According to Developmental Stage of Antibody
Table 53: Drug Targets of Antibodies for the Treatment of Mesothelioma
According to Developmental Stage of Antibody
Table 54: Drug Targets of Antibodies for the Treatment of Myelodysplastic
Syndrome According to Developmental Stage of Antibody
Table 55: Drug Targets of Antibodies for the Treatment of Myeloma
According to Developmental Stage of Antibody
Table 56: Drug Targets of Antibodies for the Treatment of Nasopharyngeal
Cancer According to Developmental Stage of Antibody
Table 57: Drug Targets of Antibodies for the Treatment of Neuroblastoma
Cancer According to Developmental Stage of Antibody
Table 58: Drug Targets of Antibodies for the Treatment of Oesophageal
Cancer According to Developmental Stage of Antibody
Table 59: Drug Targets of Antibodies for the Treatment of Ovarian Cancer
According to Developmental Stage of Antibody
Table 60: Drug Targets of Antibodies for the Treatment of Pancreatic
Cancer According to Developmental Stage of Antibody
Table 61: Drug Targets of Antibodies for the Treatment of Peritoneal
Cancer According to Developmental Stage of Antibody
Table 62: Drug Targets of Antibodies for the Treatment of Prostate Cancer
According to Developmental Stage of Antibody
Table 63: Drug Targets of Antibodies for the Treatment of Renal Cancer
According to Developmental Stage of Antibody
Table 64: Drug Targets of Antibodies for the Treatment of Sarcoma
According to Developmental Stage of Antibody
Table 65: Drug Targets of Antibodies for the Treatment of
Chemotherapy-Induced Bone Marrow Injury According to Developmental Stage of
Antibody
Table 66: Drug Targets of Antibodies for the Treatment of
Chemotherapy-Induced Anemia According to Developmental Stage of Antibody
Table 67: Drug Targets of Antibodies for the Treatment of Thyroid Cancer
According to Developmental Stage of Antibody
Table 68: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Australia
Table 69: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Belgium
Table 70: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Brazil
Table 71: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Canada
Table 72: Antibodies with Drug Target Mix and Developmental Projects by
Companies in China
Table 73: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Cuba
Table 74: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Denmark
Table 75: Antibodies with Drug Target Mix and Developmental Projects by
Companies in France
Table 76: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Germany
Table 77: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Israel
Table 78: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Italy
Table 79: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Japan
Table 80: Antibodies with Drug Target Mix and Developmental Projects by
Companies in the Netherlands
Table 81: Antibodies with Drug Target Mix and Developmental Projects by
Companies in New Zealand
Table 82: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Norway
Table 83: Antibodies with Drug Target Mix and Developmental Projects by
Companies in South Korea
Table 84: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Sweden
Table 85: Antibodies with Drug Target Mix and Developmental Projects by
Companies in Switzerland
Table 86: Antibodies with Drug Target Mix and Developmental Projects by
Companies in United Kingdom
Table 87: Antibodies with Drug Target Mix and Developmental Projects by
Companies in the USA
Table 88: Antibodies with Drug Target Mix and Developmental Projects by
Non-Industrial Bodies
View Cart
